Newly developed angiotensin II-infused experimental models in vascular biology
- PMID: 18562020
- DOI: 10.1016/j.regpep.2008.05.002
Newly developed angiotensin II-infused experimental models in vascular biology
Abstract
Angiotensin II is a major vasoactive peptide in the renin-angiotensin system (RAS). In vitro evidence demonstrates that this peptide can modulate the function of various adhesion molecules, chemokines, cytokines and growth factors, and ultimately contributes to cell proliferation, hypertrophy and inflammation. Moreover, in vivo studies further support that angiotensin II induces several vascular alterations including sustained elevations of blood pressure, enhanced inflammatory response, increased medial thickness of the aortas, and formation of aortic dissection and aneurysms. Thus, it has been a long time that angiotensin II-induced hypertension, atherosclerosis and abdominal aortic aneurysms emerge as important experimental models with respect to vascular biology. Applications of these models to investigate the vascular diseases have dramatically improved our understanding in the pathogenesis of these diseases. However, the pathophysiology of angiotensin II in vivo remains to be determined in many other vascular diseases where angiotensin II has been implicated as the detrimental factor, at least in part due to the limit availability of animal models. Recently some new exciting experimental models based on angiotensin II infusion have been reported to replicate the human diseases, such as postmenopausal hypertension, preeclampsia, vascular remodeling, vascular aging and neovascularization. In this review, we will focus on the rationales and anticipated applications of these newly developed models, with special emphasis placed on those relevant to the vascular biology. We will also discuss the limitations of the method of chronic angiotensin II infusion and additional approaches to overcome these limitations. These experimental models will provide great opportunity for us to investigate the molecular mechanisms of angiotensin II and evaluate therapeutic approaches, particularly to finely tune the potential role of RAS activation in various vascular events using genetically engineered mice.
Similar articles
-
Angiotensin II and vascular inflammation.Med Sci Monit. 2005 Jun;11(6):RA194-205. Epub 2005 May 25. Med Sci Monit. 2005. PMID: 15917731 Review.
-
Targeting the calpain/calpastatin system as a new strategy to prevent cardiovascular remodeling in angiotensin II-induced hypertension.Circ Res. 2008 Mar 28;102(6):720-8. doi: 10.1161/CIRCRESAHA.107.160077. Epub 2008 Feb 7. Circ Res. 2008. PMID: 18258859
-
Angiotensin II-mediated development of vascular diseases.Trends Cardiovasc Med. 2004 Apr;14(3):117-20. doi: 10.1016/j.tcm.2004.01.002. Trends Cardiovasc Med. 2004. PMID: 15121160 Review.
-
Angiotensin II, vascular structure and blood pressure.Kidney Int Suppl. 1992 Jun;37:S51-5. Kidney Int Suppl. 1992. PMID: 1385840 Review.
-
Inflammation may be a bridge connecting hypertension and atherosclerosis.Med Hypotheses. 2005;64(5):925-9. doi: 10.1016/j.mehy.2004.10.016. Med Hypotheses. 2005. PMID: 15780486
Cited by
-
Differential hypertensive protease expression in the thoracic versus abdominal aorta.J Vasc Surg. 2017 Nov;66(5):1543-1552. doi: 10.1016/j.jvs.2016.07.120. Epub 2016 Dec 27. J Vasc Surg. 2017. PMID: 28034583 Free PMC article.
-
Zinc, copper, and blood pressure: Human population studies.Med Sci Monit. 2013 Jan 1;19:1-8. doi: 10.12659/msm.883708. Med Sci Monit. 2013. PMID: 23291705 Free PMC article.
-
A repressor protein, Mnt, is a novel negative regulator of vascular smooth muscle cell hypertrophy by angiotensin II and neointimal hyperplasia by arterial injury.Atherosclerosis. 2013 May;228(1):90-3. doi: 10.1016/j.atherosclerosis.2013.02.033. Epub 2013 Mar 13. Atherosclerosis. 2013. PMID: 23535568 Free PMC article.
-
Interleukin-10 negatively modulates extracellular signal-regulated kinases 1 and 2 in aorta from hypertensive mouse induced by angiotensin II infusion.Fundam Clin Pharmacol. 2019 Feb;33(1):31-40. doi: 10.1111/fcp.12409. Epub 2018 Sep 7. Fundam Clin Pharmacol. 2019. PMID: 30144156 Free PMC article.
-
Angiotensin II type 1A receptors in vascular smooth muscle cells do not influence aortic remodeling in hypertension.Hypertension. 2011 Mar;57(3):577-85. doi: 10.1161/HYPERTENSIONAHA.110.165274. Epub 2011 Jan 17. Hypertension. 2011. PMID: 21242463 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical